Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tonix Pharmaceuticals Holding Corp TNXP

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800... see more

NDAQ:TNXP - Post Discussion

Tonix Pharmaceuticals Holding Corp > Tonix Pharmaceuticals Presented Data Comparing Real-World Tr
View:
Post by whytestocks on Jun 18, 2024 3:45pm

Tonix Pharmaceuticals Presented Data Comparing Real-World Tr

BREAKING NEWS: $TNXP Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) | BenzingaGap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix's two FDA-approved non-oral...TNXP - Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities